Observational study reported higher risk with sulfonylureas and basal insulin
Two commonly used diabetes drugs -- basal insulin and sulfonylureas -- were associated with significantly increased cardiovascular risk when given as second-line therapy for patients with type 2 diabetes (T2D), according to a large observational study.